{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:56:55Z","timestamp":1788267415433,"version":"build-2803163510"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>BK polyomavirus (BKPyV) reactivation causes a destructive allograft nephropathy (BKVAN) with limited treatment options. Quantitative nucleic acid testing (QNAT) of BKPyV-DNA in blood within screening programs monitors for viral reactivation but has imprecise real-world authentication.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>This prospective, single-gate, single-center, population-based cohort study evaluated the test performances of QNAT (the index test) against biopsy-proven BKVAN, verified by universal Simian virus 40 T antigen (SV40T) immunohistochemistry (the optimal reference test), in 5339 consecutive kidney transplant samples.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>BKVAN occurred in 205 tissue samples (3.8%) obtained from 1542 recipients (6.9%); classified as polyomavirus nephropathy class 1 in 26.3%, class 2 in 67.8%, and late class 3 in 5.9%. Contemporaneous QNAT<jats:sup>+<\/jats:sup> was detected in 12.7% of cases and was associated with viremia persistence, SV40T<jats:sup>+<\/jats:sup>, and cytopathic effect using multivariable analysis. The sensitivity of 97.7% and specificity of 90.7% for QNAT<jats:sup>+<\/jats:sup> to predict BKVAN were unaffected by assay methodology. SV40T<jats:sup>+<\/jats:sup> BKVAN was QNAT<jats:sup>+<\/jats:sup> in all patients except for 6 false-negative cases. A negative qualitative NAT during protocol surveillance sampling (n\u2005=\u20053667) with a specificity of 90.7% demonstrated a 99.9% negative predictive value for excluding BKVAN at a 2.6% prevalence. In contrast, QNAT exceeding 1.0E+04 BKPyV-DNA copies\/mL in viremic patients (n\u2005=\u2005679) showed a 56.3% sensitivity and a 54.6% positive predictive value. Mild BKVAN was often misclassified, with a positive likelihood ratio of 2.9.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Test performance of QNAT in transplant recipients varies markedly according to clinical context. A negative QNAT in surveillance programs reliably rules out BKVAN. However, although positive results confirm BKV reactivation, QNAT levels could not accurately distinguish tissue-invasive infection at any threshold value.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000001845","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T20:03:18Z","timestamp":1758225798000},"page":"e1845","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["The Accuracy of Blood Nucleic Acid Testing to Predict BK Polyomavirus Nephropathy Varies by Clinical Context"],"prefix":"10.1097","volume":"11","author":[{"given":"Brian J.","family":"Nankivell","sequence":"first","affiliation":[{"name":"Department of Renal Medicine, Westmead Hospital, Sydney, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"R1-20250918","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1046\/j.1600-6135.2003.00238.x","article-title":"Polyomavirus allograft nephropathy: sequential assessment of histologic viral load, tubulitis, and graft function following changes in immunosuppression.","volume":"3","author":"Celik","year":"2003","journal-title":"Am J Transplant"},{"key":"R2-20250918","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1046\/j.1600-6143.2004.00603.x","article-title":"Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load.","volume":"4","author":"Drachenberg","year":"2004","journal-title":"Am J Transplant"},{"key":"R3-20250918","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1034\/j.1600-6143.2001.10414.x","article-title":"Morphological spectrum of polyoma virus disease in renal allografts: diagnostic accuracy of urine cytology.","volume":"1","author":"Drachenberg","year":"2001","journal-title":"Am J Transplant"},{"key":"R4-20250918","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMoa020439","article-title":"Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients.","volume":"347","author":"Hirsch","year":"2002","journal-title":"N Engl J Med"},{"key":"R5-20250918","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/ajt.14292","article-title":"BK virus nephropathy: histological evolution by sequential pathology.","volume":"17","author":"Nankivell","year":"2017","journal-title":"Am J Transplant"},{"key":"R6-20250918","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1681\/ASN.V1051080","article-title":"Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease.","volume":"10","author":"Nickeleit","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R7-20250918","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1681\/ASN.2017050477","article-title":"The banff working group classification of definitive polyomavirus nephropathy: morphologic definitions and clinical correlations.","volume":"29","author":"Nickeleit","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R8-20250918","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/ncpneph0179","article-title":"The natural history, risk factors and outcomes of polyomavirus BK-associated nephropathy after renal transplantation.","volume":"2","author":"Hirsch","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"R9-20250918","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1600-6143.2009.02952.x","article-title":"BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results.","volume":"10","author":"Hardinger","year":"2010","journal-title":"Am J Transplant"},{"key":"R10-20250918","doi-asserted-by":"crossref","first-page":"256923","DOI":"10.1155\/2013\/256923","article-title":"Immunity to polyomavirus BK infection: immune monitoring to regulate the balance between risk of BKV nephropathy and induction of alloimmunity.","volume":"2013","author":"Comoli","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"R11-20250918","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1600-6143.2005.00742.x","article-title":"Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction.","volume":"5","author":"Brennan","year":"2005","journal-title":"Am J Transplant"},{"key":"R12-20250918","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1111\/j.1600-6143.2010.03310.x","article-title":"Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy.","volume":"10","author":"Schaub","year":"2010","journal-title":"Am J Transplant"},{"key":"R13-20250918","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1600-6143.2006.01296.x","article-title":"Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN).","volume":"6","author":"Wadei","year":"2006","journal-title":"Am J Transplant"},{"key":"R14-20250918","doi-asserted-by":"crossref","first-page":"e13528","DOI":"10.1111\/ctr.13528","article-title":"BK polyomavirus in solid organ transplantation\u2014guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.","volume":"33","author":"Hirsch","year":"2019","journal-title":"Clin Transplant"},{"key":"R15-20250918","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1097\/TP.0000000000004976","article-title":"The second international consensus guidelines on the management of BK polyomavirus in kidney transplantation.","volume":"108","author":"Kotton","year":"2024","journal-title":"Transplantation"},{"key":"R16-20250918","doi-asserted-by":"crossref","first-page":"e1318","DOI":"10.1097\/TXD.0000000000001318","article-title":"Economic evaluation of screening for polyomavirus infection in kidney transplant recipients: a cost-utility analysis.","volume":"8","author":"Wong","year":"2022","journal-title":"Transplant Direct"},{"key":"R17-20250918","first-page":"CD014839","article-title":"Serum and urine nucleic acid screening tests for BK polyomavirus-associated nephropathy in kidney and kidney-pancreas transplant recipients.","volume":"11","author":"Maung Myint","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"R18-20250918","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.kint.2023.07.025","article-title":"An observational cohort study of histological screening for BK polyomavirus nephropathy following viral replication in plasma.","volume":"104","author":"Cleenders","year":"2023","journal-title":"Kidney Int"},{"key":"R19-20250918","doi-asserted-by":"crossref","first-page":"e12969","DOI":"10.1111\/tid.12969","article-title":"Determination of viremia cut-off for risk to develop BKPyV-associated nephropathy among kidney transplant recipients.","volume":"20","author":"Bicalho","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"R20-20250918","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1093\/ndt\/gfn289","article-title":"Monitoring of BK virus replication in the first year following renal transplantation.","volume":"23","author":"Costa","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R21-20250918","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/tid.12164","article-title":"Currently recommended BK virus (BKV) plasma viral load cutoff of >\/=4 log10\/mL underestimates the diagnosis of BKV-associated nephropathy: a single transplant center experience.","volume":"16","author":"Hassan","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"R22-20250918","first-page":"455","article-title":"Clinical validation study of quantitative real-time PCR assay for detection and monitoring of BK virus nephropathy.","volume":"44","author":"Kudose","year":"2014","journal-title":"Ann Clin Lab Sci"},{"key":"R23-20250918","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/TP.0000000000000642","article-title":"Clinical utility of urinary cytology to detect BK viral nephropathy.","volume":"99","author":"Nankivell","year":"2015","journal-title":"Transplantation"},{"key":"R24-20250918","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/TP.0b013e31826784d8","article-title":"Risk assessment for polyomavirus nephropathy using urine cytology and the detection of decoy cells: cheap and efficient.","volume":"94","author":"Nickeleit","year":"2012","journal-title":"Transplantation"},{"key":"R25-20250918","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation.","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R26-20250918","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1097\/TXD.0000000000000641","article-title":"Clearance of BK virus nephropathy by combination antiviral therapy with intravenous immunoglobulin.","volume":"3","author":"Kable","year":"2017","journal-title":"Transplant Direct"},{"key":"R27-20250918","doi-asserted-by":"crossref","first-page":"e14367","DOI":"10.1111\/tid.14367","article-title":"A randomized, placebo-controlled, dose-escalation phase I\/II multicenter trial of low-dose cidofovir for BK polyomavirus nephropathy.","volume":"26","author":"Imlay","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"R28-20250918","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.humpath.2011.03.008","article-title":"Interobserver agreement for Polyomavirus nephropathy grading in renal allografts using the working proposal from the 10th Banff Conference on Allograft Pathology.","volume":"42","author":"Sar","year":"2011","journal-title":"Hum Pathol"},{"key":"R29-20250918","doi-asserted-by":"crossref","first-page":"e012799","DOI":"10.1136\/bmjopen-2016-012799","article-title":"STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration.","volume":"6","author":"Cohen","year":"2016","journal-title":"BMJ Open"},{"key":"R30-20250918","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/ajt.12218","article-title":"Pathology of resolving polyomavirus-associated nephropathy.","volume":"13","author":"Menter","year":"2013","journal-title":"Am J Transplant"},{"key":"R31-20250918","doi-asserted-by":"crossref","first-page":"104210","DOI":"10.1016\/j.jcv.2019.104210","article-title":"Quantification of plasma BK polyomavirus loads is affected by sequence variability, amplicon length, and non-encapsidated viral DNA genome fragments.","volume":"121","author":"Leuzinger","year":"2019","journal-title":"J Clin Virol"},{"key":"R32-20250918","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/jvi.68.4.2398-2408.1994","article-title":"A steroid hormone response unit in the late leader of the noncoding control region of the human polyomavirus BK confers enhanced host cell permissivity.","volume":"68","author":"Moens","year":"1994","journal-title":"J Virol"},{"key":"R33-20250918","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2215\/CJN.13611119","article-title":"The Importance of kidney medullary tissue for the accurate diagnosis of BK virus allograft nephropathy.","volume":"15","author":"Nankivell","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"R34-20250918","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(71)91776-4","article-title":"New human papovavirus (B.K.) isolated from urine after renal transplantation.","volume":"1","author":"Gardner","year":"1971","journal-title":"Lancet"},{"key":"R35-20250918","first-page":"352","article-title":"Human polyoma virus (HPV)\u2014a significant pathogen in renal transplantation.","volume":"15","author":"Mackenzie","year":"1978","journal-title":"Proc Eur Dial Transplant Assoc"},{"key":"R36-20250918","first-page":"105","article-title":"Human polyoma virus infection of renal allografts: histopathologic diagnosis, clinical significance, and literature review.","volume":"9","author":"Pappo","year":"1996","journal-title":"Mod Pathol"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T20:03:24Z","timestamp":1758225804000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001845","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]}}}